Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.53 (market cap $12.58B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $24.26 (market cap $141.25M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 89.1× ProShares UltraShort Bloomberg Natural Gas ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and ProShares UltraShort Bloomberg Natural Gas ETF for 10 Days on average.
| HALO | KOLD | |
|---|---|---|
Market Cap | $12.58B | $141.25M |
Volume | 2,179,278 | 5,492,367 |
Sector | Health | Leveraged / Inverse |
52-Week High | $115.22 | $49.39 |
52-Week Low | $61.63 | $13.58 |
Typical Hold Time | 1 Days | 10 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
KOLD is trading at $24.52, down 1.29% over the past day, with a bearish technical signal driven by moving averages. The stock lacks key financial ratio data, and recent news highlights volatility in natural gas markets, with record-high U.S. production and geopolitical tensions influencing sentiment.
The outlook for KOLD is clouded by weak technicals and fundamental data gaps. Investment opportunities are limited without clear earnings or valuation metrics, while risks include energy market volatility and competitive pressures from high natural gas supply.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
